Syndax Pharmaceuticals

Entinostat (internal code 17-073) is a small-molecule therapeutic candidate developed by Syndax Pharmaceuticals for the treatment of lymphoma. The program is currently in Phase 2 clinical development with an active status as of the latest milestone dated July 23, 2025. Entinostat represents Syndax's approach to addressing lymphoid malignancies through a targeted small-molecule mechanism. The company is advancing the program without disclosed partnership arrangements. Key clinical evaluation is being conducted under NCT03179930. Regulatory approval status and specific mechanism of action have not yet been disclosed. The competitive landscape for lymphoma therapeutics includes multiple approved agents spanning various mechanisms, including kinase inhibitors, monoclonal antibody conjugates, and cytokine-based therapies, as well as several investigational programs in Phase 3 development. Syndax's strategy appears focused on establishing clinical proof-of-concept in Phase 2 before advancing toward later-stage development. Expected timelines for Phase 3 initiation, regulatory filing, or approval have not yet been disclosed.

Lymphoma represents a significant oncology market with substantial unmet medical need, particularly in relapsed or refractory disease settings and in patient populations with limited treatment options or resistance to existing therapies. The competitive landscape is populated with approved agents, yet continued innovation is driven by the need for improved efficacy, reduced toxicity, and novel mechanisms to overcome resistance. Entinostat's positioning within this landscape depends on its clinical efficacy profile, safety tolerability, and potential for differentiation versus established competitors such as ibrutinib, brentuximab vedotin, and temsirolimus. The Phase 2 stage represents a critical inflection point for establishing preliminary efficacy signals and safety data that would support advancement to pivotal Phase 3 trials. Commercial significance is contingent upon demonstrating meaningful clinical benefit in a defined patient population and achieving regulatory approval in a market where multiple treatment options already exist. The lymphoma market encompasses both indolent and aggressive subtypes, with varying prognoses and treatment algorithms, creating multiple potential commercial opportunities for novel therapeutics that address specific disease biology or patient populations. Syndax's development of entinostat reflects the ongoing industry focus on lymphoid malignancies as a therapeutic priority.

Entinostat is classified as a small-molecule therapeutic candidate. The specific mechanism of action, molecular target, and route of administration have not yet been disclosed. The drug is being evaluated in lymphoma indications. Related approved therapies in the competitive set include kinase inhibitors (ibrutinib, crizotinib), monoclonal antibody-drug conjugates (brentuximab vedotin), mTOR inhibitors (temsirolimus), and cytokine-based immunotherapies (denileukin difitox). Patent status and first approval date are not yet disclosed.

Regulatory approval status for entinostat has not yet been disclosed. The program is currently in Phase 2 clinical development. FDA, EMA, PMDA (Japan), and NMPA (China) approval pathways and timelines are not yet disclosed. No breakthrough designation, fast-track status, or other expedited regulatory designations have been reported in the available facts.

Entinostat remains in early-to-mid stage clinical development with limited publicly disclosed data on efficacy, safety, or mechanism of action. The Phase 2 status as of July 2025 suggests the program is actively enrolling or analyzing data, but no interim or final results have been reported. Key future catalysts include: (1) interim or final Phase 2 efficacy and safety data; (2) potential Phase 3 initiation announcement; (3) regulatory feedback or designations; (4) publication of clinical trial results in peer-reviewed literature. Syndax's strategy appears to focus on establishing clinical proof-of-concept before advancing to pivotal trials. The competitive landscape is mature with multiple approved options, suggesting entinostat must demonstrate clear differentiation—either through superior efficacy, improved tolerability, or activity in a specific lymphoma subtype or resistant population—to achieve commercial success. The absence of disclosed partnership arrangements suggests Syndax is pursuing independent development and commercialization. Investors and stakeholders should monitor for Phase 2 data readouts and regulatory interactions that would clarify the program's clinical potential and development trajectory.